Dr. Seymour Discusses Rationale for MURANO Study in CLL

John F. Seymour, MBBS, PhD
Published: Monday, Jan 21, 2019



John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the rationale for the MURANO study in patients with chronic lymphocytic leukemia (CLL).

Novel agents have shown promise in this space, particularly venetoclax, a BCL2 inhibitor, says Seymour, but also BTK inhibitors and PI3 kinase inhibitors. The challenge with these drugs as single agents is that they have to be given continuously until disease progression. This is because the complete remission rate and minimal residual disease (MRD) negativity is relatively low. In order to bring patients off therapy, physicians need to see MRD negativity.

The combination of venetoclax and rituximab (Rituxan) has been known to achieve MRD negativity, so the MURANO trial tested this against the standard 6 cycles of bendamustine and rituximab in a time-limited fashion for patients with relapsed/refractory CLL. In updated data presented at the 2018 ASH Annual Meeting, patients treated with venetoclax had higher progression-free survival and MRD negativity rates.
SELECTED
LANGUAGE


John F. Seymour, MBBS, PhD, clinical hematologist, associate director of Clinical Research, Peter MacCallum Centre, director of the integrated Haematology Department of the Peter MacCallum Cancer Centre and the Royal Melbourne Hospital, discusses the rationale for the MURANO study in patients with chronic lymphocytic leukemia (CLL).

Novel agents have shown promise in this space, particularly venetoclax, a BCL2 inhibitor, says Seymour, but also BTK inhibitors and PI3 kinase inhibitors. The challenge with these drugs as single agents is that they have to be given continuously until disease progression. This is because the complete remission rate and minimal residual disease (MRD) negativity is relatively low. In order to bring patients off therapy, physicians need to see MRD negativity.

The combination of venetoclax and rituximab (Rituxan) has been known to achieve MRD negativity, so the MURANO trial tested this against the standard 6 cycles of bendamustine and rituximab in a time-limited fashion for patients with relapsed/refractory CLL. In updated data presented at the 2018 ASH Annual Meeting, patients treated with venetoclax had higher progression-free survival and MRD negativity rates.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 14th Annual International Symposium on Melanoma and Other Cutaneous Malignancies®Apr 30, 20192.0
Oncology Consultations®: The Advancing Role of CAR T-Cell Therapies in Hematologic MalignanciesApr 30, 20191.5
Publication Bottom Border
Border Publication
x